58774 Federal Register / Vol. 65, No. 191 / Monday, October 2, 2000 / Notices

Form name No. of

respondents

No.

responses

per

respondent

Average

burden per

response

(in hrs.)

Phase 3: attempt to get an interview ...................................................................................................... 800 1 5/60

Phase 3: Completed Follow-up Study Interviews ................................................................................... 600 1 300

Dated: September 26, 2000.

Nancy Cheal,

Acting Associate Director for Policy, Planning

and Evaluation Centers for Disease Control

and Prevention (CDC).

[FR Doc. 00–25143 Filed 9–29–00; 8:45 am]

BILLING CODE 4163–18–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[30DAY–71–00]

Agency Forms Undergoing Paperwork

Reduction Act Review

The Centers for Disease Control and

Prevention (CDC) publishes a list of

information collection requests under

review by the Office of Management and

Budget (OMB) in compliance with the

Paperwork Reduction Act (44 U.S.C.

Chapter 35). To request a copy of these

requests, call the CDC Reports Clearance

Officer at (404) 639–7090. Send written

comments to CDC, Desk Officer; Human

Resources and Housing Branch, New

Executive Office Building, Room 10235;

Washington, DC 20503. Written

comments should be received within 30

days of this notice.

Proposed Project

A Message-Based Intervention for

Technology Transfer—New—National

Institute for Occupational Safety and

Health, Centers for Disease Control and

Prevention. The mission of the National

Institute for Occupational Safety and

Health (NIOSH) is to promote safety and

health at work for all people through

research and prevention. Over 6 million

American workers are at risk for

inhalation exposure of potentially

harmful metals. Workers in mining,

construction, and related industries are

potentially exposed to airborne

contaminants such as silver, lead,

nickel, manganese, chromium and zinc

which can cause health problems

ranging from metal fume fever and

asthma to cancer and parkinsonism.

NIOSH has developed analytical

methods for portable field exposure

assessment that would help reduce

metals exposure. The goal of this project

is to increase the self-reported use of

NIOSH developed analytical methods

for field portable exposure assessment

by American industrial hygienists

across the five-year period from 2000 to

2004. To achieve this technology

transfer goal, NIOSH proposes three

aims: (1) to create, (2) implement, and

(3) evaluate a message-based

intervention targeted toward American

industrial hygienists. If this project is

successful then NIOSH will also have

developed and validated a

communication strategy that could be

adapted to other technology transfer

problems.

First, NIOSH will develop a messagebased intervention targeted toward

American industrial hygienists. To do

this, NIOSH will create and pretest the

message, channel, and receiver variables

that will compose the intervention.

Pretesting of the intervention will occur

via mailout surveys and on-site

pretesting with industrial hygienists

attending conferences sponsored by

AIHA (the American Industrial Hygiene

Association), ABIH (the American Board

of Industrial Hygiene), and ACGIH.

Pretesting will occur during the first two

years of the project (2000–1), with a

total of 1,000 industrial hygienists.

Second, NIOSH will implement the

multi-channel, multi-exposure,

message-based intervention that was

created through pretesting. NIOSH

intends to employ the following four

channels of: (1) Trade print sources

(journal and magazine), (2) web site, (3)

direct personalized mailings, and (4)

face-to-face interaction through trade

show demonstrations. The entire

population of American industrial

hygienists (approximately 13,000) will

be targeted by this intervention. The

intervention will occur across four

years, applying modifications as needed

during the time period.

Finally, NIOSH will conduct annual

surveys of randomly selected samples of

American industrial hygienists on their

self reported use of NIOSH developed

analytical methods for field portable

exposure assessment through mail-in

surveys based on standard HCRB

communication and outcome protocols.

During Year 1 (2000), a survey of 700

randomly selected industrial hygienists

will be conducted to assess baseline

levels of attitudes, knowledge and

behaviors with regard to the use of the

NIOSH developed analytical methods

prior to receiving the intervention.

During the next three years (2001–2003),

an annual survey of 700 randomly

selected industrial hygienists will be

conducted to evaluate the impact of the

message-based intervention on the use

of NIOSH analytical methods.

The estimated annualized burden is

1905 hours.

Respondents Number of respondents Number of

responses

Average

hour burden

per

response

Industrial Hygienist ............................................................ 1000 pretesting ................................................................ 1 .33

700 Baseline Survey ........................................................ 1 .25

2100 Annual Survey ......................................................... 1 5

Federal Register / Vol. 65, No. 191 / Monday, October 2, 2000 / Notices 58775

Dated: September 26, 2000.

Nancy Cheal,

Acting Associate Director for Policy,

Planning, and Evaluation, Centers for Disease

Control and Prevention (CDC).

[FR Doc. 00–25144 Filed 9–29–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Statement of Organization, Functions,

and Delegations of Authority

Part C (Centers for Disease Control

and Prevention) of the Statement of

Organization, Functions, and

Delegations of Authority of the

Department of Health and Human

Services (45 FR 67772–76, dated

October 14, 1980, and corrected at 45 FR

69296, October 20, 1980, as amended

most recently at 65 FR 41079, dated July

3, 2000) is amended to reflect the

retitling of the Division of Public Health

Systems and the Division of Media and

Training Services, Public Health

Practice Program Office, to the Division

of Public Health Systems Development

and Research and the Division of

Professional Development and

Evaluation respectively.

Section C–B, Organization and

Functions, is hereby amended as

follows:

Delete the title Division of Public

Health Systems (CH5) and insert the

title Division of Public Health Systems

Development and Research (CH5).

Delete the title Division of Media and

Training Services (CH7) and insert the

title Division of Professional

Development and Evaluation (CH7).

Dated: September 20, 2000.

Martha Katz,

Acting Director.

[FR Doc. 00–25261 Filed 9–29–00; 8:45 am]

BILLING CODE 4160–18–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 00N–1516]

Apothecon, Inc., et al.; Withdrawal of

Approval of 76 Abbreviated New Drug

Applications

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is withdrawing

approval of 76 abbreviated new drug

applications (ANDA’s). The holders of

the applications notified the agency in

writing that the drug products were no

longer marketed and requested that the

approval of the applications be

withdrawn.

EFFECTIVE DATE: October 10, 2000.

FOR FURTHER INFORMATION CONTACT:

Olivia A. Pritzlaff, Center for Drug

Evaluation and Research (HFD–7), Food

and Drug Administration, 5600 Fishers

Lane, Rockville, MD 20857, 301–594–

2041.

SUPPLEMENTARY INFORMATION: The

holders of the applications listed in the

table in this document have informed

FDA that these drug products are no

longer marketed and have requested that

FDA withdraw approval of the

applications. The applicants have also,

by their request, waived their

opportunity for a hearing.

ANDA No. Drug Applicant

60–100 Crysticillin (Penicillin G Procaine Suspension

USP).

Apothecon, Inc., P.O. Box 4500, Princeton, NJ 08543.

60–618 Grifulvin V (Griseofluvin Microsize) Tablets, 125

milligrams (mg), 250 mg, and 500 mg.

Johnson & Johnson Consumer Co, Inc., 199 Grandview Rd.,

Skillman, NJ 08858.

61–220 Opthochlor (Chloramphenicol Ophthalmic Solution

USP) 5 mg/milliliter (mL).

Parkedale Pharmaceuticals, Inc., 501 Fifth St., Bristol, TN 37620.

61–334 Bactocill (Oxacillin Sodium for Injection). SmithKline Beecham Pharmaceuticals, One Franklin Plaza, P.O.

Box 7929, Philadelphia, PA 19101.

61–449 Staphcillin (Methicillin Sodium). Apothecon, Inc.

61–452 Cloxacillin Sodium Capsules USP, 250 mg and

500 mg.

Do.

61–739 Garamycin Pediatric Injection (Gentamicin Sulfate

Injection USP).

Schering Corp., 2000 Galloping Hill Rd., Kenilworth, NJ 07033.

62–328 Erythromycin Topical Solution USP, 1.5%. Alpharma, 333 Cassell Dr., suite 3500, Baltimore, MD 21224.

62–727 Totacillin-N (Ampicillin Sodium) for Injection. Smithkline Beecham Pharmaceuticals.

62–755 Nallpen (Nafcillin Sodium Powder for Injection

USP).

Do.

70–356 Diazepam Tablets USP, 2 mg. Roxane Laboratories, Inc., P.O. Box 16532, Columbus, OH 43216.

70–357 Diazepam Tablets USP, 5 mg. Do.

70–358 Diazepam Tablets USP, 10 mg. Do.

71–010 Acetominophen Suppositories, 120 mg. Do.

71–011 Acetominophen Suppositories, 650 mg. Do.

71–018 Metaproterenol Sulfate Inhalation Solution USP,

0.6%.

AstraZeneca, L.P.

71–275 Metaproterenol Sulfate Inhalation Solution USP,

0.4%.

Do.

72–018 Droperidol Injection USP, 2.5 mg/mL. Do.

72–019 Droperidol Injection USP, 2.5 mg/mL. Do.

72–021 Droperidol Injection USP, 2.5 mg/mL. Do.

72–648 Timolol Maleate Tablets USP, 5 mg. Novopharm Limited, c/o Novopharm NC, Inc., 4700 Novopharm

Blvd., Wilson, NC 27893.

72–649 Timolol Maleate Tablets USP, 10 mg. Do.

72–650 Timolol Maleate Tablets USP, 20 mg. Do.